Plasma Soluble Fms-Like Tyrosine Kinase-1, Placental Growth Factor, and Vascular Endothelial Growth Factor System Gene Variants as Predictors of Survival in Heart Failure
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3368 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Melinda A Paterson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Heart Failure, Vascular Endothelial Growth Factor Receptor-1, Placenta Growth Factor, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Research Council of New Zealand, National Heart Foundation of Australia, Heart Foundation of New Zealand Chair of Heart Health.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), components of the vascular endothelial growth factor (VEGF) system, play key roles in angiogenesis. Reports of elevated plasma levels of sFlt-1 and PlGF in coronary heart disease and heart failure (HF) led us to investigate their utility, and VEGF system gene single nucleotide polymorphisms (SNPs), as prognostic biomarkers in HF. Methods and results ELISA assays for sFlt-1, PlGF and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed on baseline plasma samples from the PEOPLE cohort (n = 890), a study of outcomes among patients after an episode of acute decompensated HF. Eight SNPs potentially associated with sFlt-1 or PlGF levels were genotyped. sFlt-1 and PlGF were assayed in 201 subjects from the Canterbury Healthy Volunteers Study (CHVS) matched to PEOPLE participants. All-cause death was the major endpoint for clinical outcome considered. In PEOPLE participants, mean plasma levels for both sFlt-1 (125 ± 2.01 pg/ml) and PlGF (17.5 ± 0.21 pg/ml) were higher (both p < 0.044) than in the CHVS cohort (81.2 ± 1.31 pg/ml and 15.5 ± 0.32 pg/ml, respectively). sFlt-1 was higher in HF with reduced ejection fraction compared to HF with preserved ejection fraction (p = 0.005). The PGF gene SNP rs2268616 was univariately associated with death (p = 0.016), and was also associated with PlGF levels, as was rs2268614 genotype. Cox proportional hazards modelling (n = 695, 246 deaths) showed plasma sFlt-1, but not PlGF, predicted survival (hazard ratio 6.44, 95% confidence interval 2.57–16.1; p < 0.001) in PEOPLE, independent of age, NT-proBNP, ischaemic aetiology, diabetic status and beta-blocker therapy.
Conclusions
Plasma sFlt-1 concentrations have potential as an independent predictor of survival and may be complementary to established prognostic biomarkers in HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch, Christchurch, New Zealand.
- Cardiology Department, Middlemore Hospital, Auckland, New Zealand.
- Department of Cardiology, Waikato District Health Board, Hamilton, New Zealand.
- Cardiovascular Research Institute, National University of Singapore, Singapore, Singapore.
- Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand.
- School of Health Sciences, College of Health, Massey University, Wellington, New Zealand.
ORCID-Profile: Barry R Palmer
Förderung
- Health Research Council of New Zealand
- National Heart Foundation of Australia
- Heart Foundation of New Zealand Chair of Heart Health
- Heart Foundation of New Zealand Chair of Cardiovascular Studies
- Heart Foundation of New Zealand
- National Heart Foundation of New Zealand
Zitieren
APA
Paterson, M. A., Pilbrow, A. P., Frampton, C. M., Cameron, V. A., Troughton, R. W., Pemberton, C. J., Lund, M., Devlin, G. P., Richards, A. M., Doughty, R. N., & Palmer, B. R. (2024). Plasma Soluble Fms-Like Tyrosine Kinase-1, Placental Growth Factor, and Vascular Endothelial Growth Factor System Gene Variants as Predictors of Survival in Heart Failure. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3368
Vancouver
Paterson MA, Pilbrow AP, Frampton CM, Cameron VA, Troughton RW, Pemberton CJ, et al. Plasma Soluble Fms-Like Tyrosine Kinase-1, Placental Growth Factor, and Vascular Endothelial Growth Factor System Gene Variants as Predictors of Survival in Heart Failure. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3368
BibTeX
@article{Paterson2024,
author = {Paterson, Melinda A and Pilbrow, Anna P and Frampton, Chris M and Cameron, Vicky A and Troughton, Richard W and Pemberton, Chris J and Lund, Mayanna and Devlin, Gerard P and Richards, A Mark and Doughty, Robert N and Palmer, Barry R},
title = {Plasma Soluble Fms-Like Tyrosine Kinase-1, Placental Growth Factor, and Vascular Endothelial Growth Factor System Gene Variants as Predictors of Survival in Heart Failure},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3368}
}
EUVIMED